CTOs on the Move

OrthoFX

www.orthofx.com

 
OrthoFX have the best materials technology in the industry, due in large part to Loc Phan, the key scientist behind developing the first ever clear aligner. We are committed to continued polymer technology innovation by hiring a team of industry experts like Loc to understand your needs and pain points, and we can`t do it without your partnership.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.orthofx.com
  • 48890 Milmont Dr 101D
    Fremont, CA USA 94538
  • Phone: 415.936.0006

Executives

Name Title Contact Details

Funding

OrthoFX raised $13M on 07/22/2020

Similar Companies

IVX Animal Health

IVX Animal Health is a Saint Joseph, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lycored

Nutrition isn`t complicated. For us, it`s natural. We`ve been a leader in the research and development of carotenoid-based products for the last two decades and we take that role very seriously. This means we approach everything we do with a sense of wonder and a driving desire to find the best possible outcome or create the highest-quality product.

Ridgway Community Nurse Service Inc

Ridgway Community Nurse Service Inc is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cooley Dickinson Hospital

Cooley Dickinson Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Cooley Dickinson Hospital is based in Northampton, MA. You can find more information on Cooley Dickinson Hospital at www.cooley-dickinson.org

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.